Top
Summary
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
All bebtelovimab studies
 
Feedback
Home
c19early.org COVID-19 treatment researchBebtelovimabBebtelovimab (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

Outcomes in COVID-19 bebtelovimab studies

Outcomes in bebtelovimab studies. Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 Planas. mAb use may create new variants that spread globally Focosi. mAb use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape Choudhary.
0 0.5 1 1.5+ All studies 34% 6 13,329 Improvement, Studies, Patients Relative Risk Mortality 60% 4 12,478 ICU admission 59% 1 9,162 Hospitalization 33% 5 12,858 Viral clearance 15% 2 633 RCTs -46% 2 760 Peer-reviewed 46% 4 12,569 Early 34% 6 13,329 Bebtelovimab for COVID-19 c19early.org Sep 2023 Favorsbebtelovimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Early treatment 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk All studies 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk 6 bebtelovimab COVID-19 studies c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Dryden-Peterson 86% 0.14 [0.01-2.76] 0/377 3/377 Molina (PSM) 57% 0.43 [0.11-1.30] 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.078 Early treatment 60% 0.40 [0.14-1.11] 4/5,459 17/7,019 60% lower risk All studies 60% 0.40 [0.14-1.11] 4/5,459 17/7,019 60% lower risk 4 bebtelovimab COVID-19 mortality results c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.078 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Molina 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.056 Early treatment 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 59% lower risk All studies 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 59% lower risk 1 bebtelovimab COVID-19 ICU result c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.056 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Dryden-Peterson 29% 0.71 [0.32-1.59] hosp. 10/377 14/377 Molina (PSM) 56% 0.44 [0.30-0.64] hosp. 38/3,739 107/5,423 Sridhara (PSM) 11% 0.89 [0.52-1.53] hosp. 24/1,091 27/1,091 Tau​2 = 0.08, I​2 = 37.2%, p = 0.065 Early treatment 33% 0.67 [0.44-1.03] 82/5,711 152/7,147 33% lower risk All studies 33% 0.67 [0.44-1.03] 82/5,711 152/7,147 33% lower risk 5 bebtelovimab COVID-19 hospitalization results c19early.org Sep 2023 Tau​2 = 0.08, I​2 = 37.2%, p = 0.065 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Early treatment 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk All studies 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk 6 bebtelovimab COVID-19 serious outcomes c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) 4% 0.96 [0.95-0.97] viral load 125 (n) 128 (n) Tau​2 = 0.05, I​2 = 64.1%, p = 0.37 Early treatment 15% 0.85 [0.59-1.22] 33/377 26/256 15% lower risk All studies 15% 0.85 [0.59-1.22] 33/377 26/256 15% lower risk 2 bebtelovimab COVID-19 viral clearance results c19early.org Sep 2023 Tau​2 = 0.05, I​2 = 64.1%, p = 0.37 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Early treatment -46% 1.46 [0.34-6.22] 6/504 2/256 46% higher risk All studies -46% 1.46 [0.34-6.22] 6/504 2/256 46% higher risk 2 bebtelovimab COVID-19 Randomized Controlled Trials c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 151% higher risk All studies -151% 2.51 [0.10-61.1] 1/252 0/128 151% higher risk 1 bebtelovimab COVID-19 RCT mortality result c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Improvement, RR [CI] Treatment Control Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau​2 = 0.00, I​2 = 0.0%, p = 0.091 Early treatment 46% 0.54 [0.27-1.10] 9/5,364 32/7,205 46% lower risk All studies 46% 0.54 [0.27-1.10] 9/5,364 32/7,205 46% lower risk 4 bebtelovimab COVID-19 peer reviewed studies c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.091 Effect extraction pre-specified(most serious outcome) Favors bebtelovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Lilly (RCT) -201% 3.01 [0.12-73.2] death 1/127 0/128 Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Lilly (RCT) -51% 1.51 [0.26-8.90] hosp. 3/127 2/128 Lilly (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Lilly (RCT) 38% 0.62 [0.35-1.10] viral+ 16/127 26/128 Lilly (RCT) 33% 0.67 [0.38-1.17] viral+ 17/125 26/128 BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 BLAZE-4 Dougan (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 BLAZE-4 Dougan (RCT) 4% 0.96 [0.95-0.97] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 30% 0.70 [0.63-0.78] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 15% 0.85 [0.81-0.88] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 39% 0.61 [0.34-1.11] viral+ 15/125 25/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Dryden-Peterson 43% 0.57 [0.28-1.19] death/hosp. 10/377 17/377 Dryden-Peterson 29% 0.71 [0.32-1.59] hosp. 10/377 14/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Molina 59% 0.41 [0.17-1.03] ICU 6/3,739 21/5,423 Molina (PSM) 56% 0.44 [0.30-0.64] hosp. 38/3,739 107/5,423 Molina (PSM) 46% 0.54 [0.38-0.74] hosp. 48/3,739 116/5,423 Molina (PSM) -33% 1.33 [1.12-1.57] progression 260/3,739 275/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Sridhara (PSM) 25% 0.75 [0.43-1.31] death/hosp. 24/1,091 28/1,091 Sridhara (PSM) 11% 0.89 [0.52-1.53] hosp. 24/1,091 27/1,091 Bebtelovimab COVID-19 outcomes c19early.org Sep 2023 Favors bebtelovimab Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit